Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHOC-MSC trial of mesenchymal stem cells for severe community-acquired septic shock
2024-518019-20-00Phase 2Authorised
- Sponsor
- CHRU Nancy
- Start
- Oct 2021
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised trial of mesenchymal stem cells in septic shock and sepsis (2 arms), sponsored by CHRU Nancy. Primary endpoint: SOFA score at Day 7. Planned start Oct 2021; status: authorised.
02
Drugs
mesenchymal stem cells
03
Conditions
septic shocksepsis
Beyond the preview
Go deeper on 2024-518019-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518019-20-00.